General Hospital Psychiatry
Volume 25, Issue 1 , Pages 34-38 , January 2003

Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study

  • Naoshi Horikawa, M.D.

      Affiliations

    • Department of Psychiatry, Tokyo Women’s Medical University, Tokyo, Japan
    • Department of Psychiatry, Musashino Red Cross Hospital, Tokyo, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-3-3353-8111; fax: +81-3-3353-8979.
    • ,
  • Tomoko Yamazaki, M.D.

      Affiliations

    • Department of Psychiatry, Musashino Red Cross Hospital, Tokyo, Japan
    • ,
  • Namiki Izumi, M.D.

      Affiliations

    • Department of Internal Medicine, Musashino Red Cross Hospital, Tokyo, Japan
    • ,
  • Masakatsu Uchihara, M.D.

      Affiliations

    • Department of Internal Medicine, Musashino Red Cross Hospital, Tokyo, Japan

References 

  1. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C, and interferon alpha (a review). Am J Psychiatry. 2000;157:867–876
  2. Malek-Ahmadi P. Mood disorders associated with interferon treatment (theoretical, and practical considerations). Ann Pharmacother. 2001;35:489–495
  3. Fukunishi K, Tanaka H, Maruyama J, et al.  Burns in a suicide attempt related to psychiatric side effects of interferon. Burns. 1998;24:581–583
  4. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol. 1994;21:241–243
  5. O’Connor NT. Interferon beta, and suicide in multiple sclerosis. Lancet. 1996;347:1417–1418
  6. Borras C, Rio J, Porcel J, et al.  Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b. Neurology. 1999;52:1636–1639
  7. Caraceni A, Gangeri L, Martini C, et al.  Neurotoxicity of interferon-alpha in melanoma therapy (results from a randomized controlled trial). Cancer. 1998;83:482–489
  8. Hunt CM, Dominitz JA, Bute BP, et al.  Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci. 1997;42:2482–2486
  9. McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity (an investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers). Lancet. 1987;2:1175–1178
  10. Miyaoka H, Otsubo T, Kamijima K, et al.  Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry. 1999;156:1120
  11. Mohr DC, Likosky W, Dwyer P, et al.  Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. Arch Neurol. 1999;56:1263–1265
  12. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis, and mood or anxiety disorders. Lancet. 1999;354:131–132
  13. Renault PF, Hoofnagle JH, Park Y, et al.  Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med. 1987;147:1577–1580
  14. American Psychiatric Association . Diagnostic, and Statistical Manual of Mental Disorders. 4th Edition. Washington D C: American Psychiatric Association; 1994;
  15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62
  16. Simon GE. Long-term prognosis of depression in primary care. Bull World Health Organ. 2000;78:439–445
  17. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry. 1965;12:63–70
  18. Taylor JA. A personality scale of manifest anxiety. J Abnorm Psychol. 1953;48:285–290
  19. Dwight MM, Kowdley KV, Russo JE, et al.  Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res. 2000;49:311–317
  20. Conry-Cantilena C, VanRaden M, Gibble J, et al.  Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334:1691–1696
  21. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus, and depression in drug users. Am J Gastroenterol. 1998;93:785–789
  22. Noguchi S, Sata M, Suzuki H, Mizokami M, Tanikawa K. Routes of transmission of hepatitis C virus in an endemic rural area of Japan (molecular epidemiologic study of hepatitis C virus infection). Scand J Infect Dis. 1997;29:23–28
  23. de Lima MS, Hotoph M, Wessely S. The efficacy of drug treatments for dysthymia (a systematic review, and meta-analysis). Psychol Med. 1999;29:1273–1289
  24. Ruther E, Degner D, Munzel U, et al.  Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry. 1999;32:127–135
  25. Toru M, Moriya H, Yamamoto K, Shimazono Y. A double-blind comparison of sulpiride with chlordiazepoxide in neurosis. Folia Psychiatr Neurol Jpn. 1976;30:153–164
  26. Tsukamoto T, Asakura M, Tsuneizumi T, et al.  Therapeutic effects and side effects in patients with major depression treated with sulpiride once a day. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:615–618
  27. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(Suppl 1):112S–121S
  28. Niiranen A, Laaksonen R, Iivanainen M, et al.  Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatr Scand. 1988;78:622–626
  29. Bowen JD, Larson EB. Drug-induced cognitive impairment (defining the problem, and finding solutions). Drugs Aging. 1993;3:349–357
  30. Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics. 1999;40:510–512
  31. Goldman LS. Successful treatment of interferon alpha-induced mood disorder with nortriptyline. Psychosomatics. 1994;35:412–413
  32. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol. 1993;88:760–761
  33. Schramm TM, Lawford BR, Macdonald GA, Cooksley WGE. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust. 2000;173:359–361
  34. Musselman DL, Lawson DH, Gumnick JF, et al.  Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–966
  35. Merimsky O, Chaitchik S. Neurotoxicity of interferon-alpha. Anticancer Drugs. 1992;3:567–570
  36. Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol. 1988;6:355–359
  37. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient’s initial affective state. N Engl J Med. 1999;340:1370
  38. Mulder RT, Ang M, Chapman B, et al.  Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol. 2000;15:300–303
  39. Van Thiel DH, Friedlander L, Molloy PJ, et al.  Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol. 1995;7:165–168
  40. Malaguarnera M, Di Fazio I, Restuccia S, et al.  Interferon alpha-induced depression in chronic hepatitis C patients (comparison between different types of interferon alpha). Neuropsychobiology. 1998;37:93–97
  41. Horikawa N, Yamazaki T, Sagawa M, Nagata T. A case of akathisia during interferon-alpha therapy for chronic hepatitis type C. Gen Hosp Psychiatry. 1999;21:134–135

PII: S0163-8343(02)00239-6

doi: 10.1016/S0163-8343(02)00239-6

General Hospital Psychiatry
Volume 25, Issue 1 , Pages 34-38 , January 2003

Article Tools

* Image Usage & Resolution